Monoclonal gammopathy of uncertain significance
MONDO:0004225A condition characterized by the presence of a monoclonal gammopathy (MG) in which the clonal mass has not reached a predefined state in which the condition is considered malignant. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.
Also known as: MGUS, benign monoclonal gammopathy, monoclonal gammopathy Of undetermined significance (MGUS), monoclonal gammopathy of undetermined significance, monoclonal gammopathy of undetermined significance (MGUS), monoclonal gammopathy of undetermined significance (morphologic abnormality), monoclonal gammopathy of unknown significance, monoclonal gammopathy, benign
51 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Gut bacteria drug shows promise against blood disorder
Disease control CompletedThis early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobul…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Turmeric and black pepper extract shows promise in slowing early cancers
Disease control CompletedThis study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Fasting at night may cut cancer risk in people with blood disorder precursors
Disease control CompletedThis study tested whether fasting for at least 14 hours each night could help overweight people with early blood cancer conditions (MGUS, smoldering myeloma) lose weight and possibly lower their cancer risk. Twenty-three participants were randomly assigned to either the fasting p…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Farmers' pesticide use linked to blood cancer precursors
Knowledge-focused CompletedThis study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Can new scans predict myeloma before it strikes?
Knowledge-focused CompletedThis study looked at whether newer imaging techniques can better detect when a person with early blood conditions (MGUS or smoldering myeloma) is developing active multiple myeloma. Thirty-one adults with these conditions received three types of scans: a standard PET/CT, an exper…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Pee and blood may spare patients painful bone marrow needles
Knowledge-focused CompletedThis study looked at 300 people with Waldenström's macroglobulinemia or a related condition to see if blood or urine tests could detect key genetic mutations as accurately as bone marrow biopsies. The goal is to find a less invasive way to monitor the disease over time. Researche…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Blood test may spot bone damage in multiple myeloma
Knowledge-focused CompletedThis study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy contro…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC